speb/financial-data huggingface dataset:
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 3752897000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 154755168.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: 6743000.00
JBCHEPHARM.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 693734000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 24803522000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 11006120000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 19810906.15
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 1452273000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -954787000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 35538706000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 28635725000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 5724462000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 24803522000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 25290168000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 10735184000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 20258376000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 5190691000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 6447000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 49536000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 75741000.00
JBCHEPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 75741000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 360945000.00
JBCHEPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 9735837000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 14920871000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 34476710000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 3563103000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 6869188000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -7003774000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 1148998000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -158526000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 48052000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 154951521.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 35.66
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 769344000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 3499500000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -2613670000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 205149000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 155195000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 882151000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 4596353000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -1569875000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 235016000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 647135000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -720285000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 1379964000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -716041000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -56362000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 112963000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 155195000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -1569875000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 29233293000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 199910000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 669409000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 12029489000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 18533453000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 108766000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 3335023000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 3443789000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 8682261000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 490592000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 1383204000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 1383204000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 1383204000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 1383204000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 158587465.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 34.85
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 5526278000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 16484000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 0.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 7951611000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 9334815000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -156000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 882151000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 237082000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -3854850000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 2407217000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 5392447000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -327427000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 1700000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 337026000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill: 574592000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 14459138000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 7027714000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 13388784000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 22447221000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 7631000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 436519000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 436519000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 44277000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 44277000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -442130000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 40770000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 5025128000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 32804703000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -4038304000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 285134000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 199910000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 394451000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 96383000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 236387000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 332770000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 0.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -1790000000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 183900000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 7939246000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 199910000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Net Debt: 2689259000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -105958000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 5526278000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 5526278000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 5526278000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 5526278000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 5526278000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 7515092000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 5526278000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -1345042000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: -399004000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -1475170000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -1915957000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -1790000000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -399004000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 6385010000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -1258862000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -125957000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 14774155000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 16988000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 58777000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 1492076000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 183883000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 63978000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 9006163000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 5284601342.25
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 8006117000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 7526350000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 34476710000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 155194800.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 1903100000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 242000000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 1398387000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 13884546000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 412925000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 387048000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 4000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 17000000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 970000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 3294686000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 866060000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 886178000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 167019000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 3714202000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Other Special Charges: -1225000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 4563267000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1851650000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 7515092000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 114013000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -1345042000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -8688479000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -1268628000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 1965441000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 12029489000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 1383204000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 20169000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 20169000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -1790000000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 16484000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 25207217000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 7213309000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 9766000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 3818072000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 4155098000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 155194800.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 1225000.00
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 419665000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 29233293000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 14774155000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 86975342.25
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 1988814000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -1324858000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 39941271000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 29469680000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 3776559000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 29233293000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 26950360000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 10707978000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 21407818000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 2025717000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 6762000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 117620000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 328652000.00
JBCHEPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 328652000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 239545000.00
JBCHEPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 9851192000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 3424900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 8165300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 361700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 185700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 155300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 898900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 4296500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 155300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 32122300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 419600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 19133000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 111100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 816400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 927500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 6219200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 621600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 574600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 14158100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 6416700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 5436700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 32938700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 361700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 74600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 74600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 219900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 6416700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 17964200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 52200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 1641200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 155314408.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 1228400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 197400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 31967000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 13583500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 14900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 16900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 5997100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 6100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 3397600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 3663000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 155314408.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 32122300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 17964200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 40294100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 32122300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 1002100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 32122300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 8171800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 21161100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 1952600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 238100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 12913800000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 16672064000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 4478400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 38620423000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 9494800000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 4107171000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 4107171000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 8153788000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 8153788000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -7703113000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -7703113000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 1655671000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1655671000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -198257000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -198257000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Amortization: 957394000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 2504085000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 2504085000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 155364761.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 155651709.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 42.45
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 9.36
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 882151000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 3639052000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 3639052000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -1203061000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 140860000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 140860000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 155677000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 155677000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 1150910000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 1150910000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4500918000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4500918000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -2370420000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 360000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 360000000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 790910000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 790910000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -264424000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: 834164000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -498003000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 71737000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 268835000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 155677000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 155677000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -2370420000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 34333151000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 34333151000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 240027000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 616391000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 616391000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 13403164000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 3216400000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 19227419000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 19227419000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 77330000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 77330000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 138038000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 138038000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 215368000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 215368000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 6323391000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 6323391000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 622624000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 622624000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 1710369000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 1710369000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 1710369000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 464400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 752975000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 464400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 158691543.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 158876772.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 41.56
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 9.17
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1456900000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 22953000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 22953000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 52000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 8980812000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 1944800000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 10691181000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 2409200000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -76000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 1150910000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 279795000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 279795000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -5796700000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 2439416000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 2439416000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 7821437000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -322134000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -2119000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 362527000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 574592000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 574592000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 13745996000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 13745996000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 8352045000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 8352045000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 14418940000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 14418940000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 25217259000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 6278400000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 7833000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 7833000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 106896000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 14500000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 106896000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 14500000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Interest Income: 53261000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 53261000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -96155000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 45377000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 5289553000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 5289553000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 34471189000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 34471189000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -2958963000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 2783880000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 2783880000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 240027000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 394451000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 394451000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 63530000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 63530000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 63530000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 63530000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 225300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 225300000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 8788683000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 8788683000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 240027000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 56014000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 1456900000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1456900000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1456900000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1456900000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1456900000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 8873916000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 6595818000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1456900000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -227185000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: -64029000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -14500000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -1812470000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -3439155000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 0.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -64029000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -14500000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 6715827000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 6715827000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -964737000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -3439155000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 20587155000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 20587155000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 19013000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 19013000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 84194000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 84194000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1773422000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1773422000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 225289000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 225289000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 59745000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 59745000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 10362167000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 2409200000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 6351267965.56
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 1456900000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 9024498000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 8545195000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 1800000000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 38620423000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 9494800000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 155677208.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 155677208.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1168300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1168300000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 222800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 222800000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 1680285000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 1680285000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 13171404000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 13171404000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 373883000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 373883000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 51487000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 155200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 155200000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 19000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 19000000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 5676000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 144800000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 3416698000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 2245800000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 1125993000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 1125993000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 980363000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 980363000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 101254000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 101254000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 3350008000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 3350008000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Other Special Charges: -6932000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 5338417000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 5338417000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 1151120000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 1151120000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 8873916000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 1930300000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 42910000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -227185000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -12366902000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -975876000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 2264657000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 2264657000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 13403164000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 3216400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 1710369000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 464400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 22482000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 22482000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 22953000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 22953000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 29351199000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 29351199000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 10554432000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 11139000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 4298205000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 4660732000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 155677208.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 155677208.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: 6932000.00
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 549026000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 34333151000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 34333151000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 20587155000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 20587155000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 84463965.56
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 2278098000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 473400000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.25
JBCHEPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -2006708000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 42737796000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 42737796000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 34333151000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 34333151000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 278898000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 278898000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 34333151000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 34333151000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 30075228000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 7694800000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 8404645000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 8404645000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 23510377000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 23510377000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2081254000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2081254000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 10394000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 82300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 82300000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 329014000.00
JBCHEPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 329014000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 211597000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 211597000.00
JBCHEPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 12904028000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 12904028000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 4886700000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 10939400000.00